Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Pharmacologic management of high-risk neuroblastoma in children.

Ganeshan VR, Schor NF.

Paediatr Drugs. 2011 Aug 1;13(4):245-55. doi: 10.2165/11591630-000000000-00000. Review.

2.

Pharmacotherapy of neuroblastoma.

George RE, Diller L, Bernstein ML.

Expert Opin Pharmacother. 2010 Jun;11(9):1467-78. doi: 10.1517/14656566.2010.482100. Review.

PMID:
20408767
3.

A comparison of current neuroblastoma chemotherapeutics.

Castel V, Cañete A.

Expert Opin Pharmacother. 2004 Jan;5(1):71-80. Review.

PMID:
14680437
4.

High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.

Yalçin B, Kremer LC, van Dalen EC.

Cochrane Database Syst Rev. 2015 Oct 5;(10):CD006301. doi: 10.1002/14651858.CD006301.pub4. Review.

PMID:
26436598
5.

Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.

Parsons K, Bernhardt B, Strickland B.

Ann Pharmacother. 2013 Feb;47(2):210-8. doi: 10.1345/aph.1R353. Epub 2013 Feb 5. Review.

PMID:
23386066
6.

High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.

Yalçin B, Kremer LC, Caron HN, van Dalen EC.

Cochrane Database Syst Rev. 2013 Aug 22;(8):CD006301. doi: 10.1002/14651858.CD006301.pub3. Review. Update in: Cochrane Database Syst Rev. 2015;(10):CD006301.

PMID:
23970444
7.

New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence.

Schor NF.

Pharmacol Ther. 2009 Apr;122(1):44-55. doi: 10.1016/j.pharmthera.2009.01.001. Epub 2009 Jan 23. Review.

8.

Emerging drugs for neuroblastoma.

Castel V, Segura V, Berlanga P.

Expert Opin Emerg Drugs. 2013 Jun;18(2):155-71. doi: 10.1517/14728214.2013.796927. Epub 2013 May 22. Review.

PMID:
23692586
9.

Therapeutic strategies for the treatment of neuroblastoma.

Izbicka E, Izbicki T.

Curr Opin Investig Drugs. 2005 Dec;6(12):1200-14. Review.

PMID:
16370386
10.

Molecularly guided therapy of neuroblastoma: a review of different approaches.

Tonini GP, Pistoia V.

Curr Pharm Des. 2006;12(18):2303-17. Review.

PMID:
16787256
11.

Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the Neurokinin-1 Receptor System.

Berger M, VON Schweinitz D.

Anticancer Res. 2017 Nov;37(11):5911-5918. Review.

PMID:
29061769
12.

New therapeutic targets for the treatment of high-risk neuroblastoma.

Wagner LM, Danks MK.

J Cell Biochem. 2009 May 1;107(1):46-57. doi: 10.1002/jcb.22094. Review.

PMID:
19277986
13.

Ten challenges in the management of neuroblastoma.

Gains J, Mandeville H, Cork N, Brock P, Gaze M.

Future Oncol. 2012 Jul;8(7):839-58. doi: 10.2217/fon.12.70. Review.

PMID:
22830404
14.

Neuroblastoma.

Kushner BH, Cheung NK.

Pediatr Ann. 1988 Apr;17(4):269-76, 278-84. Review.

PMID:
3290814
15.

Retinoids in pediatric onco-hematology: the model of acute promyelocytic leukemia and neuroblastoma.

Masetti R, Biagi C, Zama D, Vendemini F, Martoni A, Morello W, Gasperini P, Pession A.

Adv Ther. 2012 Sep;29(9):747-62. doi: 10.1007/s12325-012-0047-3. Epub 2012 Aug 28. Review.

PMID:
22941525
16.

Intensive chemotherapy with stem cell support-experience in pediatric solid tumours.

Pinkerton CR.

Bull Cancer. 1995;82 Suppl 1:61s-65s. Review.

PMID:
7626856
17.

Ligand-targeted liposomal therapies of neuroblastoma.

Pastorino F, Marimpietri D, Brignole C, Di Paolo D, Pagnan G, Daga A, Piccardi F, Cilli M, Allen TM, Ponzoni M.

Curr Med Chem. 2007;14(29):3070-8. Review.

PMID:
18220743
18.

The mTOR signaling pathway in pediatric neuroblastoma.

Mei H, Wang Y, Lin Z, Tong Q.

Pediatr Hematol Oncol. 2013 Oct;30(7):605-15. doi: 10.3109/08880018.2013.798058. Epub 2013 May 22. Review.

PMID:
23697980
19.

Targeting focal adhesion kinase in neuroblastoma.

Gillory L, Beierle EA.

Anticancer Agents Med Chem. 2010 Dec;10(10):714-21. Review.

20.

Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?

Bellanti F, Kågedal B, Della Pasqua O.

Eur J Clin Pharmacol. 2011 May;67 Suppl 1:87-107. doi: 10.1007/s00228-010-0966-3. Epub 2011 Feb 2. Review.

Supplemental Content

Support Center